 |
N-[3-(4′,5′-bipyrimidin-2-ylamino)-4-methylphenyl]-4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]methyl}-3-(trifluoromethyl)benzamide |
|---|---|
| Trade Name | |
| Orphan Indication | Philadelphia chromosome-positive chronic myelogenous leukemia |
| USA Market Approval | USA |
| USA Designation Date | 2006-12-27 00:00:00 |
| Sponsor | CytRx Corporation;3030 Bunker Hill Street, Suite 101;San Diego, California, 92109 |
